NCT05185622View on ClinicalTrials.gov

A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

July 16, 2024

Study Completion Date

July 16, 2024

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Vamorolone

Oral administration of vamorolone for 12 weeks.

Trial Locations (5)

AB T3B 6A8

Alberta's Children Hospital, Calgary

V6H 3N1

British Columbia Children's Hospital, Vancouver

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

M5G 1X8

The Hospital for Sick Children, Toronto

H4A 3J1

Montreal Childrens Hospital, Montreal

Sponsors
All Listed Sponsors
lead

Santhera Pharmaceuticals

INDUSTRY

NCT05185622 - A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter